Deans' stroke musings: Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Saturday, April 4, 2020

Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug

Maybe you want to see what human research followup and protocols your doctors created from this in the past four and a half years. Or you could let the incompetent sleeping dogs lie. Your choice, it will just impact how well your children and grandchildren recover from a stroke.

Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug

Nat Commun. 2015 Oct 27;6:8466. doi: 10.1038/ncomms9466.

Marschallinger J^1,², Schäffner I³, Klein B^1,², Gelfert R^1,², Rivera FJ^1,², Illes S^1,², Grassner L^1,^2,⁴, Janssen M^1,², Rotheneichner P^1,^2,⁵, Schmuckermair C⁶, Coras R⁷, Boccazzi M⁸, Chishty M⁹, Lagler FB¹⁰, Renic M¹¹, Bauer HC^2,¹², Singewald N⁶, Blümcke I⁷, Bogdahn U¹³, Couillard-Despres S^2,⁵, Lie DC³, Abbracchio MP⁸, Aigner L^1,².

Author information

Abstract

As human life expectancy has improved rapidly in industrialized societies, age-related cognitive impairment presents an increasing challenge. Targeting histopathological processes that correlate with age-related cognitive declines, such as neuroinflammation, low levels of neurogenesis, disrupted blood-brain barrier and altered neuronal activity, might lead to structural and functional rejuvenation of the aged brain. Here we show that a 6-week treatment of young (4 months) and old (20 months) rats with montelukast, a marketed anti-asthmatic drug antagonizing leukotriene receptors, reduces neuroinflammation, elevates hippocampal neurogenesis and improves learning and memory in old animals. By using gene knockdown and knockout approaches, we demonstrate that the effect is mediated through inhibition of the GPR17 receptor. This work illustrates that inhibition of leukotriene receptor signalling might represent a safe and druggable target to restore cognitive functions in old individuals and paves the way for future clinical translation of leukotriene receptor inhibition for the treatment of dementias.